Compare HWC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWC | TGTX |
|---|---|---|
| Founded | 1883 | 1993 |
| Country | United States | United States |
| Employees | 3603 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.9B |
| IPO Year | N/A | 2008 |
| Metric | HWC | TGTX |
|---|---|---|
| Price | $63.60 | $33.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $76.14 | $49.80 |
| AVG Volume (30 Days) | 773.2K | ★ 1.9M |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $11.66 | $49.30 |
| Revenue Next Year | $4.36 | $24.55 |
| P/E Ratio | $12.48 | ★ $11.39 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.90 | $25.37 |
| 52 Week High | $75.43 | $46.48 |
| Indicator | HWC | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 66.49 |
| Support Level | $63.03 | $33.58 |
| Resistance Level | $64.42 | $37.11 |
| Average True Range (ATR) | 1.32 | 1.50 |
| MACD | 0.33 | 0.37 |
| Stochastic Oscillator | 81.51 | 95.92 |
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.